Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Pair of Molecular Regulators Maintains Normal Eosinophil Levels

By LabMedica International staff writers
Posted on 18 Nov 2013
An international team of cell biologists have identified the mechanism that regulates production of eosinophils by the blood marrow, which may lead to development of drugs to control diseases caused by an excess of these cells.

Eosinophils are immune cells responsible for combating certain infections such as multicellular parasites. More...
Along with mast cells, they also control mechanisms associated with allergy and asthma. Eosinophils develop in the bone marrow under the control of the central eosinophil growth factor interleukin 5 (IL-5) before migrating into the blood. In normal individuals, eosinophils make up about 1%–6% of white blood cells, and are about 12–17 micrometers in size. Under normal conditions, eosinophils are found in the medulla and the junction between the cortex and medulla of the thymus and in the lower gastrointestinal tract, ovary, uterus, spleen, and lymph nodes but not in the lung, skin, or esophagus. The presence of eosinophils in these latter organs is associated with disease.

Investigators at Tel Aviv University (Israel) and Cincinnati Children's Hospital Medical Center (Ohio, USA) searched for the molecular signals that regulate eosinophil production.

They reported in the November 10, 2013, online edition of the journal Nature Immunology that IL-5 activity in eosinophils was regulated by the paired immunoglobulin-like receptors PIR-A and PIR-B. PIR-A countered the activity of IL-5 and triggered eosinophil apoptosis. However, in eosinophilia the activity of PIR-A was blocked by overexpression of PIR-B, and the eosinophils did not die.

Experiments using a model system of asthmatic mice that lacked PIR-B showed that these animals had little expansion of eosinophils in their blood and lungs and less asthmatic inflammation in their lungs than normal mice. The lack of PIR-B prevented eosinophils from reaching harmful levels.

"The fundamental knowledge we have gained may one day yield new therapies to treat devastating eosinophilic disorders," said senior author Dr. Ariel Munitz, senior lecturer in microbiology and clinical immunology at Tel Aviv University.

Researchers are now seeking drugs to either enhance the toxic effect of PIR-A on eosinophils or to weaken PIR-B activity in order to reduce its inhibitory effect on PIR-A.

Related Links:

Tel Aviv University
Cincinnati Children's Hospital Medical Center



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.